跳轉至內容
Merck
全部照片(1)

文件

A7655

Sigma-Aldrich

阿替洛尔

≥98% (TLC), powder, β₁-adrenoceptor antagonist

同義詞:

(±)-4-[2-羟基-3-[(1-甲基乙基)氨基] 丙氧基] 苯乙酰胺, 4-[2'-羟基-3'-(异丙胺基)丙氧基] 苯乙酰胺

登入查看組織和合約定價


About This Item

經驗公式(希爾表示法):
C14H22N2O3
CAS號碼:
分子量::
266.34
EC號碼:
MDL號碼:
分類程式碼代碼:
12352200
PubChem物質ID:
NACRES:
NA.77

product name

阿替洛尔, ≥98% (TLC), powder

化驗

≥98% (TLC)

形狀

powder

顏色

white to off-white

溶解度

H2O: 0.3 mg/mL
DMSO: 18 mg/mL
ethanol: 3.4 mg/mL

起源

AstraZeneca

SMILES 字串

CC(C)NCC(O)COc1ccc(CC(N)=O)cc1

InChI

1S/C14H22N2O3/c1-10(2)16-8-12(17)9-19-13-5-3-11(4-6-13)7-14(15)18/h3-6,10,12,16-17H,7-9H2,1-2H3,(H2,15,18)

InChI 密鑰

METKIMKYRPQLGS-UHFFFAOYSA-N

基因資訊

human ... ADRB1(153)
rat ... Adrb1(24925)

尋找類似的產品? 前往 產品比較指南

應用

阿替洛尔是一种 β 肾上腺素能受体阻断药,用于治疗高血压。阿替洛尔具有抗心绞痛和抗心律失常的作用。

生化/生理作用

选择性 β1 肾上腺素受体拮抗剂;抗高血压;抗心绞痛;抗心律失常。

特點和優勢

该化合物在受体分类和信号转导手册中β-肾上腺素能受体页面中进行了详细介绍。想要浏览手册的其他页面, 请单击此处
该化合物由 AstraZeneca 公司开发。若要浏览其他制药公司研发的化合物和批准的药物/候选药物列表,请单击此处

其他說明

固体的有效期至少为 3 年。

儲存類別代碼

11 - Combustible Solids

水污染物質分類(WGK)

WGK 2

閃點(°F)

Not applicable

閃點(°C)

Not applicable

個人防護裝備

Eyeshields, Gloves, type N95 (US)


分析證明 (COA)

輸入產品批次/批號來搜索 分析證明 (COA)。在產品’s標籤上找到批次和批號,寫有 ‘Lot’或‘Batch’.。

已經擁有該產品?

您可以在文件庫中找到最近購買的產品相關文件。

存取文件庫

Ganesha Rai et al.
Journal of medicinal chemistry, 52(20), 6474-6483 (2009-09-19)
Schistosomiasis is a chronic parasitic disease affecting hundreds of millions of individuals worldwide. Current treatment depends on a single agent, praziquantel, raising concerns of emergence of resistant parasites. Here, we continue our explorations of an oxadiazole-2-oxide class of compounds we
Hsin-Hui Chiu et al.
Mayo Clinic proceedings, 88(3), 271-276 (2013-01-17)
To assess the tolerability and efficacy of the investigational use of the angiotensin II receptor blocker losartan added to β-blockade (BB) to prevent progressive aortic root dilation in patients with Marfan syndrome (MFS). Between May 1, 2007, and September 31
Tzu-Heng Huang et al.
International journal of molecular sciences, 22(21) (2021-11-14)
Thoracic aortic aneurysm (TAA) formation is a multifactorial process that results in diverse clinical manifestations and drug responses. Identifying the critical factors and their functions in Marfan syndrome (MFS) pathogenesis is important for exploring personalized medicine for MFS. Methylenetetrahydrofolate reductase
Ronald V Lacro et al.
The New England journal of medicine, 371(22), 2061-2071 (2014-11-19)
Aortic-root dissection is the leading cause of death in Marfan's syndrome. Studies suggest that with regard to slowing aortic-root enlargement, losartan may be more effective than beta-blockers, the current standard therapy in most centers. We conducted a randomized trial comparing
Sripal Bangalore et al.
The American journal of medicine, 127(10), 939-953 (2014-06-15)
Debate exists about the efficacy of β-blockers in myocardial infarction and their required duration of usage in contemporary practice. We conducted a MEDLINE/EMBASE/CENTRAL search for randomized trials evaluating β-blockers in myocardial infarction enrolling at least 100 patients. The primary outcome

我們的科學家團隊在所有研究領域都有豐富的經驗,包括生命科學、材料科學、化學合成、色譜、分析等.

聯絡技術服務